Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02248051

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

Acute Kidney Injury (Nontraumatic) Clinical Trial

Official title:
An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury

Clinical Trial Summary

The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10, at potentially therapeutic doses, in the target patient population comprised of subjects with Stage 3 and 4 chronic kidney injury (CKI). In addition, associated pharmacodynamic (PD) effects of CXA-10 will be investigated.

Clinical Trial Description

This will be a multi-center, open-label study, single-dose study with CXA-10 in subjects with CKI. At total of 12 subjects will be enrolled into two equal groups according to their baseline estimated glomerular filtration rate (eGFR: 15 - 39 or 40 - 59 mL/min/1.73m2). All subjects will receive a single dose infusion of CXA-10 emulsion. Since this is the first administration of CXA-10 to a non-healthy volunteer population, a conservative approach is being taken to ensure safety. Thus, the first 2 subjects from each group will be dosed at one dose level below the highest safe dose level administered in the FIH study. If this dose is found to be safe in this specific subject population, the remainder of the 4 subjects in each group will receive the highest safe dose from the FIH study; otherwise, the remainder will receive the initial dose. The doses administered in this study will not exceed the highest exposures achieved in the FIH study, and doses may need to be adjusted to lower levels, based on further evaluation of current pharmacokinetic data, to ensure the appropriate the exposure level. Safety, PK and PD assessments will be conducted over approximately 18 days following each dosing session. There will be a follow-up visit approximately 1 week after dosing. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02248051
Study type Interventional
Source Complexa, Inc.
Contact
Status Completed
Phase Phase 1
Start date September 2014
Completion date September 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT03244514 - Biomarker-guided Implementation of the AKI Bundle N/A
Withdrawn NCT04598516 - Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Recruiting NCT05275218 - Effect of an Intervention to Prevent Acute Kidney Injury Versus Standard Care in High-risk Patients After Major Surgery N/A
Recruiting NCT06259760 - AKI Risk Factors Analysis After Intentional Hypotensive Anesthesia
Recruiting NCT06295393 - Renin Angiotensin Aldosterone System In Septic Kids
Completed NCT03453996 - Contrast RISK (Reducing Injury Sustained by Kidneys) N/A
Recruiting NCT02095275 - Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients N/A
Not yet recruiting NCT03369561 - Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for Aki in Critical Care Patients N/A
Completed NCT05612802 - A New Marker for Early Diagnosis of Pneumoperitoneum-Related Acute Kidney Injury: Insulin-Like Growth Factor-1 (IGF-1) N/A
Not yet recruiting NCT03830450 - Biomarkers of Acute Kidney Injury in Cardiac Surgery
Completed NCT04592406 - Data on the Prevention of Complications of Prophylactic Intravenous Hydration in Patients With eGFR < 30
Completed NCT02127190 - Study of CXA-10 in Healthy Volunteers Phase 1